

Supplementary Information

Synthesis and Application of a Novel Poly-L-phenylalanine Electroactive Macromonomer as Matrix for the Biosensing of ‘Abused Drug’ Model

Tulay Yilmaz^{1,2}, Emine Guler^{1,2}, Z. Pinar Gumus², Huseyin Akbulut³, Ebru Aldemir², Hakan Coskunol², Demet Goen Colak³, Ioan Cianga^{3,4}, Shuhei Yamada⁵, Suna Timur^{1,2}, Takeshi Endo⁵, Yusuf Yagci^{3*}*

¹Ege University, Faculty of Science, Biochemistry Department, 35100 Bornova, Izmir/Turkey.

²Ege University, Institute of Drug Abuse Toxicology&Pharmaceutical Sciences, 35100 Bornova, Izmir/Turkey

³Istanbul Technical University, Department of Chemistry, Faculty of Science and Letters, Istanbul/Turkey

⁴"Petru Poni" Institute of Macromolecular Chemistry, Iasi, 41A Grigore Ghica Voda Alley, 700487, Romania

⁵Molecular Engineering Institute, Kinki University, 11-6 Kayanomori, Iizuka, Fukuoka, 820-8555, Japan.

Table of Contents

Fig. S1. The ^1H -NMR spectra in CDCl_3 of the intermediates used for the initiator synthesis: (A) **EDOT-NO₂-BTDA, 3** and (B) **EDOT-NH₂-BTDA, 4** in Scheme 1. P3

Fig. S2. IR spectra of initiator **EDOT-NH₂-BTDA, 4** and of the organic intermediate used for its synthesis P4

Fig. S3. IR spectrum of macromonomer **EDOT-BTDA-PPhe** P5

Fig. S4. Influence of interferants including BSA (1.0%), 0.5 μM of metamphetamine, 3-acetamidophenol,codeine. (Error bars shows \pm S.D). P6




Figure S1. The ^1H -NMR spectra in CDCl_3 of the intermediates used for the initiator synthesis: (A) **EDOT-NO₂-BTDA, 3** and (B) **EDOT-NH₂-BTDA, 4** in Scheme 1.




Fig. S2. IR spectra of the initiator, **EDOT-NH₂-BTDA, 4** and of the organic intermediate used for its synthesis




Fig. S3. IR spectrum of the macromonomer **EDOT-BTDA-PPhe**




Fig. S4. Influence of interferants including BSA (1.0%), 0.5 μ M of metamphetammine, 3-acetamidophenol, codeine. (Error bars shows \pm S.D).